Castle Biosciences, Inc.’s DecisionDx-Melanoma test stratifies melanoma-specific survival across histological subtypes in patients with cutaneous melanoma, according to a study presented at the 2025 Fall Clinical Dermatology Conference in 2025, in Las Vegas, NV.
DecisionDx-Melanoma is a 31-gene expression profile test.
In a real-world cohort of 13,560 patients with stage I–III cutaneous melanoma from Castle’s ongoing collaboration with the National Cancer Institute’s Surveillance, Epidemiology and End Results (NCI’s SEER) Program Registries, DecisionDx-Melanoma stratified melanoma-specific survival (MSS) across different tumor subtypes. For example, five-year MSS in nodular melanoma was 98.5% for patients with Class 1A (lowest risk) test results versus 82.3% for patients with Class 2B (highest risk) test results. Similar stratification was observed across superficial spreading, lentigo maligna, and unspecified subtypes.
“This study is particularly important as it demonstrates that DecisionDx-Melanoma provides consistent risk stratification across varying types of melanoma and reinforces its value in providing important prognostic information to inform risk-aligned management plans, even for patients with different subtypes of melanoma,” says Etan Marks, DO, Board-certified Pathologist, Hematopathologist, and Dermatopathologist at Advanced Dermatology in Delray Beach, FL, in a news release.
